文献速递乳腺癌支持与姑息治疗

乳腺癌后妊娠:系统综述与荟萃分析

Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Clin Oncol · 2021-07-01

该系统综述与荟萃分析纳入39项研究,涉及8,093,401名一般人群女性和112,840例乳腺癌患者(其中7,505例诊断后妊娠)。乳腺癌幸存者后续妊娠可能性显著低于一般人群(RR 0.40,95%CI 0.32-0.49),且剖宫产、低出生体重、早产和小于胎龄儿风险较高,但未观察到先天异常风险显著增加;诊断后妊娠者无病生存(HR 0.66)和总生存(HR 0.56)更优。

要点

  • 乳腺癌幸存者后续妊娠率显著低于一般人群(RR 0.40)。
  • 妊娠者剖宫产、低出生体重、早产及小于胎龄儿风险升高。
  • 诊断后妊娠与更好的无病生存和总生存相关。

核心结论

  • 乳腺癌幸存者妊娠具有安全性证据,支持将患者妊娠意愿纳入生存者照护计划。

研究设计与样本

  • 系统综述与荟萃分析,检索纳入39项研究,涉及8,093,401名一般人群女性和112,840例乳腺癌患者,其中7,505例诊断后妊娠。

主要发现

  • 乳腺癌幸存者后续妊娠可能性显著低于一般人群(RR 0.40,95%CI 0.32-0.49)。
  • 乳腺癌幸存者剖宫产(OR 1.14,95%CI 1.04-1.25)、低出生体重(OR 1.50,95%CI 1.31-1.73)、早产(OR 1.45,95%CI 1.11-1.88)和小于胎龄儿(OR 1.16,95%CI 1.01-1.33)风险显著高于一般人群,尤其是有既往化疗暴露者。
  • 未观察到先天异常或其他生殖并发症风险显著增加。
  • 与诊断后未妊娠的乳腺癌患者相比,妊娠者无病生存(HR 0.66,95%CI 0.49-0.89)和总生存(HR 0.56,95%CI 0.45-0.68)更优。

临床怎么用

  • 应向乳腺癌幸存者提供妊娠安全性的 reassuring 证据,并将妊娠意愿纳入生存者照护计划。
  • 对有既往化疗暴露的乳腺癌幸存者,妊娠应加强产科监测以管理低出生体重、早产等风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Many patients and physicians remain concerned about the potential detrimental effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and maternal safety. This systematic review and meta-analysis aimed at providing updated evidence on these topics. METHODS: A systematic literature review was conducted to identify studies including patients with a pregnancy after BC (PROSPERO number CRD42020158324). Likelihood of pregnancy after BC, their reproductive outcomes, and maternal safety were assessed. Pooled relative risks, odds ratios (ORs), and hazard ratios (HRs) with 95% CIs were calculated using random effects models. RESULTS: Of 6,462 identified records, 39 were included involving 8,093,401 women from the general population and 112,840 patients with BC of whom 7,505 had a pregnancy after diagnosis. BC survivors were significantly less likely to have a subsequent pregnancy compared with the general population (relative risk, 0.40; 95% CI, 0.32 to 0.49). Risks of caesarean section (OR, 1.14; 95% CI, 1.04 to 1.25), low birth weight (OR, 1.50; 95% CI, 1.31 to 1.73), preterm birth (OR, 1.45; 95% CI, 1.11 to 1.88), and small for gestational age (OR, 1.16; 95% CI, 1.01 to 1.33) were significantly higher in BC survivors, particularly in those with previous chemotherapy exposure, compared with the general population. No significantly increased risk of congenital abnormalities or other reproductive complications were observed. Compared to patients with BC without subsequent pregnancy, those with a pregnancy had better disease-free survival (HR, 0.66; 95% CI, 0.49 to 0.89) and overall survival (HR, 0.56; 95% CI, 0.45 to 0.68). Similar results were observed after correcting for potential confounders and irrespective of patient, tumor, and treatment characteristics, pregnancy outcome, and timing of pregnancy. CONCLUSION: These results provide reassuring evidence on the safety of conceiving in BC survivors. Patients' pregnancy desire should be considered a crucial component of their survivorship care plan.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol. 2021. PMID: 34197218. doi:10.1200/JCO.21.00535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。